Yi-Ming Hua Taiwan

• From AKI to Recovery: Medication Reconciliation and Polypharmacy Management
  Chia-Chi Chen Speaker From AKI to Recovery: Medication Reconciliation and Polypharmacy Management

  Shu-Wen Lin Moderator
• Cardio-Renal Syndrome in the ICU: Pharmacological Challenges in Multi-Organ Support
  Ya-Tzu Chang Speaker Cardio-Renal Syndrome in the ICU: Pharmacological Challenges in Multi-Organ SupportThis lecture will provide an overview of pharmacological management in cardiorenal syndrome and discuss its clinical application and therapeutic dilemmas through case-based discussion. Cardiorenal syndrome refers to a pathophysiological condition in which dysfunction of the heart or kidney induces acute or chronic dysfunction in the other organ. Pharmacological strategies include decongestion therapy and medications with cardiorenal protective effects, such as RAAS inhibitors, ARNIs, MRAs, and SGLT2 inhibitors. In clinical practice, treatment decisions must consider the patient’s hemodynamic status, renal function, electrolyte abnormalities, and overall clinical stability. The goal is to balance therapeutic benefits and potential harms while optimizing cardiac and renal protection in critically ill patients.

  Chian-Ying Chou Moderator
• Coffee Break
• Nephrotoxic Drug Stewardship (NDS): Leveraging Real-World Data for AKI Prevention
  Yi-Ming Hua Speaker Nephrotoxic Drug Stewardship (NDS): Leveraging Real-World Data for AKI Prevention藥物及腎毒性物質暴露是住院病人急性腎損傷（AKI）重要且可介入的危險因子。腎毒性藥物管理（NDS）並非單純停用腎毒性藥物，而是透過腎功能動態監測、腎毒性負荷評估、劑量調整、治療藥物監測、交互作用辨識、替代藥物選擇及用藥整合，在治療效益與腎臟安全之間取得平衡。電子病歷中的腎功能、用藥暴露、藥物濃度、共病及臨床結局等真實世界資料，可用於建立高風險分層與臨床決策支援。然而，單獨的電子警示未必能改善結果，必須結合具體可執行的建議、藥師介入及跨專業追蹤。本演講將以腎功能相關劑量調整及多重腎毒性藥物暴露為例，說明如何建立「風險辨識、即時介入、成效追蹤、回饋改善」的 NDS 模式，以降低藥物相關 AKI，同時維持必要治療的有效性。

  Hui-Chen Su Moderator
• Optimizing Pre-ESRD Care: Impact of Pharmacist-Led Clinics
  Yen-Hao Liao Speaker Optimizing Pre-ESRD Care: Impact of Pharmacist-Led ClinicsChronic kidney disease (CKD) is associated with complex medication regimens, polypharmacy, and an increased risk of drug-related problems, particularly in patients with pre-end-stage renal disease (Pre-ESRD). This session will highlight the role of pharmacist-led clinics in optimizing medication therapy management within a multidisciplinary care model. Drawing on real-world clinical experience and research findings, the presentation will discuss how pharmacist interventions can improve medication adherence, identify and resolve drug-related problems, reduce inappropriate medication use, and support better clinical outcomes. The session will also explore the evolving role of clinical pharmacists in delivering patient-centered care and enhancing the quality of Pre-ESRD management.

  Hui-Yu Chen Moderator
• Using Meta-Analysis to Evaluate the Risk of AKI Associated with IVI Drugs
  Shih-Chieh Shao Speaker Using Systematic Review and Meta-Analysis to Evaluate the Risk of AKI Associated with IVI DrugsIntravitreal anti-vascular endothelial growth factor (anti-VEGF) drugs are widely used to treat retinal diseases, but concerns remain regarding their potential systemic effects, including acute kidney injury (AKI). This presentation will demonstrate how systematic review and meta-analysis can be applied to evaluate rare safety outcomes associated with intravitreal therapies.

  Kai-Cheng Chang Moderator
• Panel Discussion & Q&A